Skip to main content

belantamab mafodotin

Generic: belantamab mafodotin·Brand: Blenrep

belantamab mafodotin: 7 clinical trials tracked.

belantamab mafodotin evidence translation

What we can confirm

7 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about belantamab mafodotin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 2 study sponsors
Clinical Trial Registry Records (7)

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

NCT07720843Registry updated 2026-07-22·Phase 1
Not yet recruiting

Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs)

Interventionalopen50 targetStarted 2026-09Completion 2032-03Montefiore Medical Center

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

NCT06232044Registry updated 2026-08-05·Phase 1/Phase 2
Recruiting

Primary endpoint: Maximum tolerated dose (MTD) of iberdomide (Phase I)

InterventionalRandomizedopen88 targetStarted 2025-04Completion 2030-0843 sites · United StatesAlliance for Clinical Trials in Oncology

A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT05922501Registry updated 2026-01-14·Phase 2
Recruiting

Primary endpoint: Overall Response Rate (ORR)

Interventionalopen50 targetStarted 2024-05Completion 2030-122 sites · United StatesMassachusetts General Hospital

A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT05145816Registry updated 2026-08-19·Phase 1/Phase 2
Recruiting

Primary endpoint: Safety/Tolerability as measured by number of subjects with dose limiting toxicity (Part 1)

Interventionalopen37 targetStarted 2024-02Completion 2027-093 sites · United StatesUniversity of Texas Southwestern Medical Center

Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma

NCT05789303Registry updated 2026-09-23·Phase 2
Recruiting

Primary endpoint: Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort)

Interventionalopen83 targetStarted 2023-05Completion 2028-072 sites · United StatesUniversity of Chicago

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

NCT04643002Registry updated 2026-06-16·Phase 1/Phase 2·SNY
Recruiting

Primary endpoint: Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab

InterventionalRandomizedopen258 targetStarted 2021-01Completion 2028-0426 sites · Australia, France, Germany, Greece…Sanofi

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

NCT02343042Registry updated 2026-07-15·Phase 1/Phase 2·KPTI
Recruiting

Primary endpoint: Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)

InterventionalRandomizedopen300 targetStarted 2015-10Completion 2027-0425 sites · Canada, United StatesKaryopharm Therapeutics Inc